Combinatorial Therapy Shows Early Promise in Patients With Relapsed Small Cell Lung Cancer
PHILADELPHIA – The PARP inhibitor olaparib (Lynparza) in combination with the chemotherapeutic agent temozolomide (Temodar) showed clinical efficacy in...
PHILADELPHIA – The PARP inhibitor olaparib (Lynparza) in combination with the chemotherapeutic agent temozolomide (Temodar) showed clinical efficacy in...
PHILADELPHIA – Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high...
Now accepting submissions for publication PHILADELPHIA – The American Association for Cancer Research (AACR) is launching a new journal,...
PHILADELPHIA – Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer,...
PHILADELPHIA – A risk prediction model developed using clinical and radiological features could stratify individuals presenting with a lung...
PHILADELPHIA – Inflammatory and immune-regulatory mechanisms were found to be altered in animal models and in archived prostate cancer...
PHILADELPHIA – Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life,...
PHILADELPHIA – A large study of postmenopausal women indicated that quitting cigarette smoking was associated with significantly reduced risk...
PHILADELPHIA: – Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and...
PHILADELPHIA: – Low rates of physician-patient discussions about lung cancer screening have declined further since 2012 and were not...